CD133+CD44+ population efficiently enriches colon cancer initiating cells

Naotsugu Haraguchi, Masahisa Ohkuma, Hiroyuki Sakashita, Shinji Matsuzaki, Fumiaki Tanaka, Koshi Mimori, Yukio Kamohara, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Background: Previous reports have demonstrated that CD133+ cells or CD44+ cells might be cancer initiating cells (CIC) of colon cancer. However, the association between the two cell types is unclear. In this study, we evaluated the tumorigenicity of each population of human colon cancer divided by CD133 and CD44 using non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. Methods: Using the colon cancer cell lines HT29 and Caco2 we evaluated the change of expression status of CD133 or CD44 by a treatment with sodium butyrate (NaBT) that can induce cellular differentiation. Next, we prepared ten clinical samples of colon cancer and analyzed the expression and tumorigenicity of CD133 and CD44. Results: With NaBT treatment, CD44 expression was greatly downregulated in both HT29 and Caco2 (HT29: nontreatment versus treatment; 77.8% versus 0.6%, Caco2: 14.0% versus 0.4%, respectively), more than CD133 expression (HT29: nontreatment versus treatment; 90.1% versus 67.7%, Caco2: 98.9% versus 76.3%, respectively). In clinical samples, the percentages of CD133+ cells and CD44+ cells varied from 0.3% to 82.0% (mean 35.5%), and from 11.5% to 58.4% (mean 30.0%), respectively. Subcutaneous injection of CD133+ or CD44+ cells made a tumor in all mice (3/3 and 4/4, respectively). The combined analysis of CD133 and CD44 revealed that only the CD133+CD44 + population had the ability to produce a tumor (3/3). Conclusion: The findings demonstrate that, at present, the CD133+CD44+ population may be the best to identify tumor initiating cells of human colon cancer.

Original languageEnglish
Pages (from-to)2927-2933
Number of pages7
JournalAnnals of Surgical Oncology
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 1 2008

Fingerprint

Colonic Neoplasms
Population
Neoplasms
Butyric Acid
SCID Mice
Neoplastic Stem Cells
Subcutaneous Injections
Therapeutics
Down-Regulation
Cell Line

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

CD133+CD44+ population efficiently enriches colon cancer initiating cells. / Haraguchi, Naotsugu; Ohkuma, Masahisa; Sakashita, Hiroyuki; Matsuzaki, Shinji; Tanaka, Fumiaki; Mimori, Koshi; Kamohara, Yukio; Inoue, Hiroshi; Mori, Masaki.

In: Annals of Surgical Oncology, Vol. 15, No. 10, 01.10.2008, p. 2927-2933.

Research output: Contribution to journalArticle

Haraguchi, N, Ohkuma, M, Sakashita, H, Matsuzaki, S, Tanaka, F, Mimori, K, Kamohara, Y, Inoue, H & Mori, M 2008, 'CD133+CD44+ population efficiently enriches colon cancer initiating cells', Annals of Surgical Oncology, vol. 15, no. 10, pp. 2927-2933. https://doi.org/10.1245/s10434-008-0074-0
Haraguchi, Naotsugu ; Ohkuma, Masahisa ; Sakashita, Hiroyuki ; Matsuzaki, Shinji ; Tanaka, Fumiaki ; Mimori, Koshi ; Kamohara, Yukio ; Inoue, Hiroshi ; Mori, Masaki. / CD133+CD44+ population efficiently enriches colon cancer initiating cells. In: Annals of Surgical Oncology. 2008 ; Vol. 15, No. 10. pp. 2927-2933.
@article{bb59a747058847cc8e4e019d258a7c54,
title = "CD133+CD44+ population efficiently enriches colon cancer initiating cells",
abstract = "Background: Previous reports have demonstrated that CD133+ cells or CD44+ cells might be cancer initiating cells (CIC) of colon cancer. However, the association between the two cell types is unclear. In this study, we evaluated the tumorigenicity of each population of human colon cancer divided by CD133 and CD44 using non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. Methods: Using the colon cancer cell lines HT29 and Caco2 we evaluated the change of expression status of CD133 or CD44 by a treatment with sodium butyrate (NaBT) that can induce cellular differentiation. Next, we prepared ten clinical samples of colon cancer and analyzed the expression and tumorigenicity of CD133 and CD44. Results: With NaBT treatment, CD44 expression was greatly downregulated in both HT29 and Caco2 (HT29: nontreatment versus treatment; 77.8{\%} versus 0.6{\%}, Caco2: 14.0{\%} versus 0.4{\%}, respectively), more than CD133 expression (HT29: nontreatment versus treatment; 90.1{\%} versus 67.7{\%}, Caco2: 98.9{\%} versus 76.3{\%}, respectively). In clinical samples, the percentages of CD133+ cells and CD44+ cells varied from 0.3{\%} to 82.0{\%} (mean 35.5{\%}), and from 11.5{\%} to 58.4{\%} (mean 30.0{\%}), respectively. Subcutaneous injection of CD133+ or CD44+ cells made a tumor in all mice (3/3 and 4/4, respectively). The combined analysis of CD133 and CD44 revealed that only the CD133+CD44 + population had the ability to produce a tumor (3/3). Conclusion: The findings demonstrate that, at present, the CD133+CD44+ population may be the best to identify tumor initiating cells of human colon cancer.",
author = "Naotsugu Haraguchi and Masahisa Ohkuma and Hiroyuki Sakashita and Shinji Matsuzaki and Fumiaki Tanaka and Koshi Mimori and Yukio Kamohara and Hiroshi Inoue and Masaki Mori",
year = "2008",
month = "10",
day = "1",
doi = "10.1245/s10434-008-0074-0",
language = "English",
volume = "15",
pages = "2927--2933",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - CD133+CD44+ population efficiently enriches colon cancer initiating cells

AU - Haraguchi, Naotsugu

AU - Ohkuma, Masahisa

AU - Sakashita, Hiroyuki

AU - Matsuzaki, Shinji

AU - Tanaka, Fumiaki

AU - Mimori, Koshi

AU - Kamohara, Yukio

AU - Inoue, Hiroshi

AU - Mori, Masaki

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Background: Previous reports have demonstrated that CD133+ cells or CD44+ cells might be cancer initiating cells (CIC) of colon cancer. However, the association between the two cell types is unclear. In this study, we evaluated the tumorigenicity of each population of human colon cancer divided by CD133 and CD44 using non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. Methods: Using the colon cancer cell lines HT29 and Caco2 we evaluated the change of expression status of CD133 or CD44 by a treatment with sodium butyrate (NaBT) that can induce cellular differentiation. Next, we prepared ten clinical samples of colon cancer and analyzed the expression and tumorigenicity of CD133 and CD44. Results: With NaBT treatment, CD44 expression was greatly downregulated in both HT29 and Caco2 (HT29: nontreatment versus treatment; 77.8% versus 0.6%, Caco2: 14.0% versus 0.4%, respectively), more than CD133 expression (HT29: nontreatment versus treatment; 90.1% versus 67.7%, Caco2: 98.9% versus 76.3%, respectively). In clinical samples, the percentages of CD133+ cells and CD44+ cells varied from 0.3% to 82.0% (mean 35.5%), and from 11.5% to 58.4% (mean 30.0%), respectively. Subcutaneous injection of CD133+ or CD44+ cells made a tumor in all mice (3/3 and 4/4, respectively). The combined analysis of CD133 and CD44 revealed that only the CD133+CD44 + population had the ability to produce a tumor (3/3). Conclusion: The findings demonstrate that, at present, the CD133+CD44+ population may be the best to identify tumor initiating cells of human colon cancer.

AB - Background: Previous reports have demonstrated that CD133+ cells or CD44+ cells might be cancer initiating cells (CIC) of colon cancer. However, the association between the two cell types is unclear. In this study, we evaluated the tumorigenicity of each population of human colon cancer divided by CD133 and CD44 using non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. Methods: Using the colon cancer cell lines HT29 and Caco2 we evaluated the change of expression status of CD133 or CD44 by a treatment with sodium butyrate (NaBT) that can induce cellular differentiation. Next, we prepared ten clinical samples of colon cancer and analyzed the expression and tumorigenicity of CD133 and CD44. Results: With NaBT treatment, CD44 expression was greatly downregulated in both HT29 and Caco2 (HT29: nontreatment versus treatment; 77.8% versus 0.6%, Caco2: 14.0% versus 0.4%, respectively), more than CD133 expression (HT29: nontreatment versus treatment; 90.1% versus 67.7%, Caco2: 98.9% versus 76.3%, respectively). In clinical samples, the percentages of CD133+ cells and CD44+ cells varied from 0.3% to 82.0% (mean 35.5%), and from 11.5% to 58.4% (mean 30.0%), respectively. Subcutaneous injection of CD133+ or CD44+ cells made a tumor in all mice (3/3 and 4/4, respectively). The combined analysis of CD133 and CD44 revealed that only the CD133+CD44 + population had the ability to produce a tumor (3/3). Conclusion: The findings demonstrate that, at present, the CD133+CD44+ population may be the best to identify tumor initiating cells of human colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=51649099207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649099207&partnerID=8YFLogxK

U2 - 10.1245/s10434-008-0074-0

DO - 10.1245/s10434-008-0074-0

M3 - Article

VL - 15

SP - 2927

EP - 2933

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -